A systematic review of the effectiveness and cost-effectiveness of palivizumab (Synagis(R)) in the prevention of respiratory syncytial virus (RSV) infection in infants at high risk of infection
Simpson S, Burls A
Record ID 32001000999
This report aims to assess the effectiveness and cost-effectiveness of palivizumab (Synagis(R)) in the prevention of respiratory syncytial virus (RSV) infection in infants at high risk of infection.
Authors' recommendations: Palivizumab appears to be an effective in preventing serious lower respiratory-tract infection caused by RSV requiring hospitalisation in high-risk infants. However, in our base-case cost-effectiveness model palivizumab was not good value for money if used in all children who meet the licensed indication. However, this is not how the drug is currently being used by clinicians in the UK who reserve it for those children at greatest risk. A sensitivity analysis varying the probability of hospitalisation in the absence of prophylaxis shows that palivizumab becomes increasingly cost effective as the probability of hospitalisation increases. When the probability is 31% or greater the incremental cost effectiveness ratio (ICER) drops to below 30,000 GBP per life year gained. The IMpact RSV published trial data does not permit an estimation of prognostic indicators.
Authors' methods: Systematic review
Project Status: Completed
URL for project: http://www.birmingham.ac.uk/Documents/college-mds/haps/projects/WMHTAC/REPreports/2001/Palivizumab_final_post_panel.pdf
Year Published: 2001
URL for published report: http://www.birmingham.ac.uk/research/activity/mds/projects/HaPS/PHEB/WMHTAC/REP/reports-list.aspx
English language abstract: An English language summary is available
Publication Type: Not Assigned
- Costs and Cost Analysis
- Respiratory Syncytial Virus Infections
- Respiratory Syncytial Virus, Human
Organisation Name: West Midlands Health Technology Assessment Collaboration
Contact Address: Elaena Donald-Lopez, West Midlands Health Technology Assessment Collaboration, Department of Public Health and Epidemiology, University of Birmingham, Edgbaston, Birmingham B15 2TT Tel: +44 121 414 7450; Fax: +44 121 414 7878
Contact Name: firstname.lastname@example.org
Contact Email: email@example.com
Copyright: University of Birmingham
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.